Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer Interventions: Drug: TQB2450 +Anlotinib+Docetaxel; Drug: TQB2450 +Androtinib Placebo+Docetaxel Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
Conditions: Locally Advanced Unresectable Esophageal Squamous Carcinoma Interventions: Drug: Docetaxel for Injection (Albumin-bound); Drug: SG001; Drug: Cisplatin for injection; Drug: Paclitaxel; Radiation: Simultaneous Radiotherapy Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
Conditions: Oral Squamous Cell Carcinoma Interventions: Drug: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: SHR-A1811; Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Conditions: Advanced Cancer Interventions: Drug: AB801; Drug: Zimberelimab; Drug: Docetaxel Sponsors: Arcus Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: BL-B01D1; Drug: capecitabine; Drug: gemcitabine; Drug: docetaxel Sponsors: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Conditions: Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Aromatase inhibitor; Drug: Docetaxel injection; Drug: Epirubicin Hydrochloride Injection; Drug: Cyclophosphamide injection Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
Conditions: Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Interventions: Drug: Cetuximab; Drug: Zimberelimab; Drug: Docetaxel; Drug: Cisplatin Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy; Pembrolizumab Interventions: Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Nedaplatin; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Liposomal paclitaxel; Drug: Fluorouracil Sponsors: Beijing Tongren Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Conditions: Breast Cancer Interventions: Drug: JSKN003; Drug: Capecitabine tablets; Drug: Gemcitabine hydrochloride for injection; Drug: Vinorelbine tartrate injection; Drug: Paclitaxel for injection (albumin-bound type); Drug: Docetaxel injection; Drug: Eribulin mesylate injection Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Docetaxel; Drug: Pemetrexed Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Conditions: Prostate Cancer Interventions: Drug: Docetaxel; Drug: ADT; Drug: Abiraterone Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Condition: HER2-PositiveRecurrent or Metastatic Breast Cancer Interventions: Drug: SHR-A1811 Injection; Drug: SHR-A1811 Injection ； Pertuzumab Injection; Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer Interventions: Drug: SHR-A1811 Injection; Drug: SHR-A1811 Injection ； Pertuzumab Injection; Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions: Head Neck; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Pembrolizumab; Drug: Magrolimab; Drug: cetuximab; Drug: Docetaxel Sponsors: M.D. Anderson Cancer Center; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
